BioCryst Pharmaceuticals (BCRX) said Monday it has been awarded a US Department of Health and Human Services contract worth up to $69 million over five years to provide up to 95,625 doses of Rapivab for the treatment of influenza.
Under the contract, BioCryst will supply injections to the Center for the Strategic National Stockpile for an initial 12 months, with four optional 12-month ordering periods. The company said it plans to provide 19,125 shots by next September for $13.9 million.
Price: 7.70, Change: +0.08, Percent Change: +1.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments